mASCARA team at ESCP in Dublin, presenting our local data on the management of anal HSIL in women. Our audit highlighted that out of 91 women with anal cancer (between 2001 and 2022) only 1 was being monitored for anal HSIL. 25% had a previous diagnosis of genital HSIL and/or cancer, recognised risk factors. Moreover 35% of these women presented with stage 3 disease. All of the above highlighting the need to improve anal cancer prevention strategies for women, who have been repeatedly shown to be more affected by the pathology and present with more advanced disease than men.